Why is ocugen (ocgn) stock up 10% today?
Mar 15, 2022 · Under the deal, Ocugen takes home 45% profits from vaccines distributed in the United States and Canada. This means that even if China or other countries outside North America purchased Covaxin,...
Why did ocugen stock skyrocket on Tuesday?
Ocugen (OCGN) is conducting the OCU-002 study to support its BLA for the approval of Covaxin in the United States. The FDA places a clinical hold on this study. American City Business Journals.
Should you buy ocugen stock after analyst upgrades?
Feb 02, 2021 · The stock price of Ocugen Inc (NASDAQ: OCGN) — a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19 — is trading at over 70% today. This is why it happened. Investors are responding to Ocugen and vaccine innovation leader Bharat Biotech …
Is ocugen stock finally showing signs of weakness?
Mar 17, 2022 · This clinical-stage biopharmaceutical company has surged in interest, particularly due to its partnership with Bharat Biotech to develop a …
Why did OCGN stock increase?
Why Agenus Stock Is Crushing It Today In response to the impressive clinical progress of Agenus' anti-cancer checkpoint inhibitor platform, Wainwright raised its 12-month price target on the biotech's shares to $14 ahead of the opening bell this morning.Mar 12, 2022
Why did Ocugen go up today?
Why Ocugen Stock Is Jumping Today The company didn't announce any new developments. However, reports of increasing new COVID-19 cases in various parts of the world appear to be fueling investors' optimism about the prospects for COVID-19 vaccine Covaxin.
Is OCGN expected to go up?
Ocugen Inc (NASDAQ:OCGN) The 3 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 8.00, with a high estimate of 15.00 and a low estimate of 6.00. The median estimate represents a +140.24% increase from the last price of 3.33.
Is OCGN good stock to buy?
Is OCUGEN Stock a good buy in 2022, according to Wall Street analysts? The consensus among 3 Wall Street analysts covering (NASDAQ: OCGN) stock is to Hold OCGN stock.
Who is making Covaxin?
COVAXIN®, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV).
What is the prediction for OCGN stock?
Stock Price Forecast The 4 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 7.00, with a high estimate of 15.00 and a low estimate of 4.00. The median estimate represents a +167.18% increase from the last price of 2.62.
Why is OCGN stock dropping?
The steep decline came after the company announced that the U.S. Food and Drug Administration (FDA) won't grant Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin in children ages two to 18.Mar 4, 2022
Why is OCGN stock falling?
Shares of Ocugen (NASDAQ: OCGN) were falling 7.8% as of 11:15 a.m. ET on Tuesday. The decline is a continuation of the sell-off that began last week after Ocugen announced the Food and Drug Administration (FDA) rejected Emergency Use Authorization (EUA) for the pediatric use of COVID-19 vaccine Covaxin.Mar 8, 2022
Is Ocugen a buy Zacks?
See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.93%2Buy18.44%3Hold9.99%4Sell5.61%2 more rows
Who bought OCGN stock?
Top 10 Owners of Ocugen IncStockholderStakeShares bought / soldBlackRock Fund Advisors5.21%+18,773The Vanguard Group, Inc.4.69%-245,162Geode Capital Management LLC1.52%-82,481JPMorgan Asset Management (UK) Lt...1.49%+3,197,6156 more rows
What does Ocugen Inc do?
Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases.
Is Ocugen a buy right now?
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last year. There are currently 3 hold ratings and 2...
How has Ocugen's stock been impacted by Coronavirus (COVID-19)?
Ocugen's stock was trading at $0.3612 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organiz...
When is Ocugen's next earnings date?
Ocugen is scheduled to release its next quarterly earnings announcement on Friday, May 6th 2022. View our earnings forecast for Ocugen .
How were Ocugen's earnings last quarter?
Ocugen, Inc. (NASDAQ:OCGN) posted its quarterly earnings data on Friday, February, 25th. The company reported ($0.07) EPS for the quarter, meeting...
What price target have analysts set for OCGN?
5 analysts have issued 1-year price targets for Ocugen's shares. Their forecasts range from $4.00 to $15.00. On average, they anticipate Ocugen's s...
Who are Ocugen's key executives?
Ocugen's management team includes the following people: Shankar Musunuri , Chairman & Chief Executive Officer ( LinkedIn Profile ) Sanjay Subram...
Who are some of Ocugen's key competitors?
Some companies that are related to Ocugen include ImmunityBio (IBRX) , Bavarian Nordic A/S (BVNRY) , Twist Bioscience (TWST) , Iovance Biothera...
What other stocks do shareholders of Ocugen own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Ocugen investors own include Onconova Therapeutics (ONTX)...
What is Ocugen's stock symbol?
Ocugen trades on the NASDAQ under the ticker symbol "OCGN."
Is Ocugen a buy right now?
What stocks does MarketBeat like better than Ocugen?
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Ocugen stock.
When is Ocugen's next earnings date?
Wall Street analysts have given Ocugen a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ocugen wasn't one of them.
How were Ocugen's earnings last quarter?
Ocugen is scheduled to release its next quarterly earnings announcement on Friday, November 5th 2021.#N#View our earnings forecast for Ocugen.
How has Ocugen's stock price been impacted by Coronavirus (COVID-19)?
Ocugen, Inc. (NASDAQ:OCGN) released its earnings results on Friday, August, 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.10.#N#View Ocugen's earnings history.
What price target have analysts set for OCGN?
Ocugen's stock was trading at $0.3612 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OCGN stock has increased by 1,879.5% and is now trading at $7.15.#N#View which stocks have been most impacted by COVID-19.
Who are some of Ocugen's key competitors?
5 equities research analysts have issued 12 month price targets for Ocugen's shares. Their forecasts range from $4.50 to $11.00. On average, they anticipate Ocugen's stock price to reach $7.66 in the next year.
Investors are reacting positively to an analyst's upgrade
Some companies that are related to Ocugen include Adaptive Biotechnologies (ADPT), Kodiak Sciences (KOD), Recursion Pharmaceuticals (RXRX), Abcam (ABCM), Sana Biotechnology (SANA), Editas Medicine (EDIT), Ablynx (ABLYF), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Bavarian Nordic A/S (BVNRY), Kymera Therapeutics (KYMR), SpringWorks Therapeutics (SWTX), Relay Therapeutics (RLAY), Translate Bio (TBIO) and BioCryst Pharmaceuticals (BCRX).#N#View all of OCGN's competitors..
What happened
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
So what
Shares of Ocugen ( NASDAQ:OCGN) were soaring 17.4% higher as of 11:53 a.m. EST on Thursday. The big gain came after H.C. Wainwright analyst Swayampakula Ramakanth upgraded the stock to a buy rating from neutral.
Now what
Should investors buy a biotech stock like Ocugen just because an analyst upgrades it? Nope. However, it's wise to examine why an analyst thinks highly (or negatively) of a stock.
When is the Ocugen class action lawsuit?
The enthusiasm about Ocugen could evaporate if Covaxin doesn't make it to the U.S. market. Ocugen has already begun talking with the U.S. Food and Drug Administration (FDA) about a potential path to EUA and ultimately approval.
Who is investigating Ocugen?
(NASDAQ: OCGN) and certain of its top executives with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers of Ocugen securities between February 2, 2021 and June 10, 2021, inclusive (the "Class Period").
Is there a cost to participate in class action lawsuit in 2021?
Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.